Form 4: Seres Therapeutics Executive Acquires Stock Options

Thomas DesRosier, Chief Legal Officer and EVP of Seres Therapeutics, acquired stock options for 650,000 shares at an exercise price of $0.782 on February 7, 2025.

Summary

• On February 7, 2025, Thomas DesRosier, the Chief Legal Officer and EVP of Seres Therapeutics, acquired stock options.
• The options are for 650,000 shares of Seres Therapeutics common stock.
• The exercise price of the options is $0.782 per share.
• The options vest as to 25% of the shares on February 7, 2026, with the remaining shares vesting in 12 equal quarterly installments thereafter.
• The expiration date for the options is February 6, 2035.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation, and does not contain information that would significantly impact sentiment.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term performance.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders, incentivizing long-term value creation.

Key Dates